Compare Natera Inc. Common Stock (NTRA) vs Planet Labs (PL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Planet Labs — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Planet Labs trades at $13.87 (market cap $5.52B). The key difference: Natera Inc. Common Stock is far larger — about 10.3× Planet Labs's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Planet Labs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Planet Labs for 6 Days on average.
| NTRA | PL | |
|---|---|---|
Market Cap | $57.03B | $5.52B |
Volume | 1,131,157 | 10,123,547 |
Sector | Health | Industrials |
52-Week High | $425.64 | $51.40 |
52-Week Low | $179.42 | $11.16 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $56.18B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Planet Labs (PL) trades at $15.16, down 5.01% on the day, reflecting ongoing bearish technical pressure despite recent satellite launches and government contract wins. The company shows revenue growth potential with $378 million projected for 2026, but faces significant profitability challenges with a -95.13% net income margin and negative ROE of -71.97%. Analyst sentiment remains positive with 13 buy ratings and a $32.50 consensus price target, though technical indicators signal bearish momentum.
The stock presents a high-risk opportunity with substantial upside potential if execution improves, but current financial performance and bearish technicals warrant caution. Key catalysts include defense contract execution and satellite deployment success, while risks include persistent losses, competitive pressure from SpaceX, and valuation concerns at current P/S of 13.35.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Planet Labs
Planet Labs operates Earth-imaging satellites and provides geospatial data products. Its imagery and analytics help governments and businesses monitor changes across the planet.
Read more on PL →
